NDAORALTABLET
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ATACAND (candesartan cilexetil) by ANI Pharmaceuticals is angiotensin-converting enzyme (ace, kininase ii). First approved in 1998.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATACAND (candesartan cilexetil) is an oral angiotensin II receptor blocker (ARB) approved in 1998 for hypertension management. It selectively blocks AT1 receptors to prevent vasoconstriction and aldosterone secretion, reducing blood pressure independently of ACE inhibitor pathways. The drug is indicated for hypertension in adults and pediatric patients.
$0.002BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spending ($2M), signaling reduced brand investment and team contraction.
Mechanism of Action
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ATACAND at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.